Plus Therapeutics(US:PSTV) ZACKS·2025-10-30 23:46Core Insights - Plus Therapeutics reported a quarterly loss of $0.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.02, and a significant improvement from a loss of $0.46 per share a year ago [1] - The company posted revenues of $1.4 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 36.79%, and a slight decrease from $1.46 million in the same quarter last year [2] - Plus shares have declined approximately 52.9% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.02 on revenues of $2.17 million, and for the current fiscal year, it is -$0.10 on revenues of $6.8 million [7] Industry Context - The Medical - Drugs industry, to which Plus belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]